Codiak BioSciences Inc. (CDAK) News
Filter CDAK News Items
CDAK News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
Latest CDAK News From Around the Web
Below are the latest news stories about CODIAK BIOSCIENCES INC that investors may wish to consider to help them evaluate CDAK as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayGood morning! |
Codiak BioSciences to Participate 5th Annual Evercore ISI HealthCONx ConferenceCAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that management will be participating in the 5th Annual Evercore ISI HealthCONx Conference, a virtual conference. Codiak’s Chief Executive Officer, Douglas E. Williams, Ph.D., will participate in a fireside chat on Wednesday, November 30 at 8:00 am ET and the Co |
Codiak Presents Preclinical Data on exoASO™-STAT6 and exoASO™-C/EBPβ Programs at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting– exoASO-STAT6 demonstrated durable pharmacokinetic/pharmacodynamic profile in preclinical models; biomarkers with clinical translational potential identified, providing a rationale for selecting cancer subtypes for treatment with exoASO-STAT6 – – Systemically administered exoASO-C/EBPβ demonstrated extra-hepatic delivery and potent systemic anti-tumor activity across multiple myeloid-derived suppressor cell (MDSC) rich tumor models – – A Phase 1 clinical trial of exoASO-STAT6 in patients with a |
Codiak BioSciences Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagCodiak BioSciences ( NASDAQ:CDAK ) Third Quarter 2022 Results Key Financial Results Revenue: US$522.0k (down 55% from... |
Codiak BioSciences, Inc. (CDAK) Reports Q3 Loss, Lags Revenue EstimatesCodiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 6.10% and 70.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
Codiak BioSciences Reports Third Quarter 2022 Financial Results and Operational Progress– Patient enrollment continuing in Phase 1 clinical trial of exoASO™-STAT6 in patients with advanced hepatocellular carcinoma; preliminary data anticipated during 1H 2023 – – Presented preclinical data showing exoVACC™ pan beta coronavirus vaccine, supported by CEPI, elicits broad protective immunity against variants of SARS-CoV-2 and other potentially human transmissible animal coronaviruses – – Two preclinical abstracts accepted at SITC 2022 for exoASO-STAT6 and exoASO™-C/EBPβ – CAMBRIDGE, Mas |
Vertex (VRTX) Beats on Q3 Earnings, Ups 2022 Sales GuidanceVertex Pharmaceuticals' (VRTX) third-quarter 2022 earnings and sales beat estimates. VRTX also raises its revenue guidance for 2022. The stock rises in the after-market trading. |
BioMarin (BMRN) Q3 Earnings Beat, Sales Miss, Ups Voxzogo ViewBioMarin Pharmaceutical's (BMRN) third-quarter 2022 earnings beat estimates, but sales slightly miss the mark. |
Biogen (BIIB) Beats on Q3 Earnings & Sales, Raises 2022 OutlookBiogen (BIIB) beats third-quarter estimates for earnings and sales. Stock rises in pre-market as management raises the company's full-year 2022 financial guidance. |
All You Need to Know About Codiak BioSciences, Inc. (CDAK) Rating Upgrade to Strong BuyCodiak BioSciences, Inc. (CDAK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |